Kornimate/medical-research-clean huggingface dataset:
baliao acupoint stimulation totreat functional constipation

Conditions: Functional Constipation (FC)

Summary: this study is a randomized controlled trial that explores how a specific acupuncture treatment might help people with functional constipation. the investigators are testing the idea that a treatment called "acupuncture at the baliao acupoints" could work by changing the way certain parts of the brain connect and function. these brain changes might help improve gut function and relieve constipation symptoms. the investigators will work with people who have functional constipation. some participants will receive the real baliao acupoint thread embedding, while others will get a sham acupuncture as a comparison. using special brain imaging techniques, the investigators will look at how the brain's connections and structures change. the investigators will also track how often participants have bowel movements, the consistency of their stools, and their overall symptoms and quality of life. by comparing these results, the investigators hope to understand how the baliao acupoint treatment works and why it might be effective for constipation.


Eligibility criteria:
inclusion criteria: * age:18 years or older. * diagnosed with functional constipation according to the rome iv criteria. * the participant has not received any treatment for functional constipation in the past two weeks (except for emergency interventions). * right-handed. * signed a written informed consent form to participate in this study. exclusion criteria: * presence of organic constipation, drug-induced constipation, or systemic constipation. * presence of metallic foreign bodies in the body, pacemakers, or other contraindications for mri examination. * communication disorders or unwillingness to cooperate with treatment.

Keywords: functional constipation fmri
statistical learning as a predictor of attention bias modification outcome

Conditions: Social Anxiety Disorder

Summary: this study examines whether the ability to extract statistical properties from the environment among treatment-seeking patients with social anxiety disorder can predict therapeutic response to attention bias modification (abm), namely, reduction in symptoms of social anxiety following abm therapy.

all participants received 6 sessions of abm therapy away from threat. at baseline participants also completed a gold standard statistical learning task aimed to assess participants' capacity for the extraction of statistical regularity from the environment. the aim of the study is to determine whether the basic ability to extract rules from the environment at baseline could predict clinical improvement of social anxiety symptoms.

Eligibility criteria:
inclusion criteria: * a signed consent form * a primary diagnosis of social anxiety disorder * an age of 18-65 exclusion criteria: * any history or present diagnosis of psychosis * high risk for harm to self or others * concurrent posttraumatic stress disorder, eating disorder, or bipolar disorder * a diagnosis of a neurological disorder (i.e., epilepsy, brain injury) * drug or alcohol misuse * a pharmacological treatment that is not stabilized in the past 3 months * any concurrent psychotherapy

Keywords: attention-bias modification statistical learning social anxiety disorder treatment outcome
the study of percutaneous mechanical thrombectomy treating acute deep vein thrombosis of lower extremities

Conditions: Pharmacomechanical Thrombolysis; Deep Vein Thrombosis

Summary: this study is a prospective, multicenter, real world, observational study intended to understand tmechanical thrombectomy in the treatment of acute deep venous thrombosis of lower extremities, it is estimated that 600 patients with dvt were enrolled in the group at 24 centers nationwide from may 2022 to may2024. we can obtain data on the incidence of sequelae of deep venous thrombosis after pmt, and analyze the factors that may affect the efficacy of pmt.

through inclusion and exclusion criteria, 600 patients were collected. this experiment was an observational study case series, and no control group was established. the patency of the lower extremity veins was assessed by lower extremity venous ultrasound or lower extremity venography. according to the postoperative symptoms and signs of the patients, the villata score, (veins qol)/sym questionnaire and vcss score were used to understand the pts situation.postoperative clinical follow-up was performed at 6 months, 12 months, 18 months, and 24 months. the main endpoints were the patency rate of lower extremity deep veins at 6 months after operation and the incidence of pts (villalta score) at 2 years after operation.

Eligibility criteria:
inclusion criteria: 1. the symptoms of deep venous thrombosis of lower extremities occurred within 14 days (including 14 days)； 2. lower extremity deep venous thrombosis involving iliac vein or / and femoral vein ; 3. obtain the informed consent of all patients. exclusion criteria: 1. patients with a previous history of ipsilateral proximal lower limb deep venous thrombosis ; 2. patients who are prohibited from thrombolytic therapy; 3. inferior vena cava compression syndrome； 4. allergic to heparin, low molecular weight heparin or contrast medium; 5. patients who have participated in clinical trials of other drugs or medical devices that interfere with this clinical trial in the past 3 months; 6. patients who do not want to participate in this trial; 7. patients with poor compliance, or those who the researchers think are not suitable for selection.

Keywords: pharmacomechanical thrombolysis deep vein thrombosis post-thromboticsyndrome
hemopatch as a tool to prevent biliary fistula in liver surgery.

Conditions: Biliary Fistula; Surgery

Summary: the aim of the study is to investigate the use of hemopatch to prevent biliary fistula in patients submitted to surgery for malignancy.

background: biliary fistula (bf) is one of the most common sources of post hepatectomy morbidity. international study group of liver surgery (isgls) define bf as increased bilirubin concentration in the drain at least 3 times greater than the serum bilirubin concentration on or after postoperative day (pod) 3. bf is graded into grade a, b and c, based on the clinical impact on the postoperative course. considering isgls definition, the incidence of bf ranges from 4,4% to 27,2%. the definition developed in humanitas research hospital (hrh), defines bf as bilirubin concentration in the drain fluid greater than 10 mg/dl on or after pod 3. in this case, the incidence is around 8%. various topical haemostatic agents have been developed for liver resection area management their usefulness in preventing bf by using a sealing product on the resection surface still remains unclear and needs to be assessed. objective: this study aimed to assess the clinical validation of hemopatch to prevent post-operative biliary fistula. secondarily, it is aimed to evaluate the clinical validity of the two proposed definition of biliary fistula. methods: according to the incidence of bf in our previous series (considering isgls definition), we designed a randomized controlled study on 220 patients, who underwent hepatic resection from 2018 to 2020. patients were randomized to treatment group a (hemopatch) and standard group b (tisseal and tabotamp). both isgls and hrh definitions of bf were considered. all patients were systematically drained. drains were maintained at least 5 days, and bilirubin was measured on pods 3, 5, and 7. drains were removed if the bilirubin concentration in the drain fluid was less than 10 mg/dl on pod 7. a statistical analysis to compare perioperative variables between two groups was performed. then, a multivariate analysis was performed to identify potential risk factors for bf.

Eligibility criteria:
inclusion criteria: * all patients submitted to liver surgery for malignancies. * \>18 years of age. exclusion criteria: * biliary reconstruction * other associated visceral resections
the validation process for confirmation of the french version of the pediatric quality of life inventory :pedsqltm.

Conditions: Duchenne Muscular Dystrophy

Summary: there isn't specific health related quality of life measure for children with dmd in french. the aim of this study is to validate the french version of the pediatric quality of life inventory 3.0 duchenne muscular dystrophy module with a multicentric study. the investigators will evaluate the following psychometric properties : convergent validity, internal validity, inter-rater reliability. the investigators would like to be able to use this scientific tool in future clinical trials.

the duchenne muscular dystrophy, the commonest form of dystrophy, is an x-linked, recessive neuromuscular disease, in which there is an absence of the protein dystrophin. this chronic and progressive disease leads to an inevitable loss of autonomy (muscle weakness, respiratory and cardiac failure). with better multidisciplinary care, life expectancy has increased but also morbidity. from now one, the evaluation of the quality of life of children with dmd is necessary in therapeutic trials. given the specificities of the disease, it seems appropriate to have a specific scale. in the literature there isn't quality of life scale specific to duchenne muscular dystrophy in french version. the only specific scale that exists is the specific module pedsqltm dmd that was validated in english version in 2012. this scale is relevant for assessing the quality of life in clinical trials and in daily clinical practice given its psychometric properties (good internal consistency close to 0.8).the main hypothesis that we formulate is to validate the french translation of the pediatric module of duchenne muscular dystrophy of the pedsql ™ 3.0 scale.

Eligibility criteria:
inclusion criteria: * boys aged 7 to 18, with genomic duchenne muscular dystrophy whose parents (mother and / or father) or direct grandparents do not oppose. exclusion criteria: * inability for the child to understand the issues * absence of direct parents or grandparents * child receiving antidepressant treatment * non french speaking child * duchenne muscular dystrophy girls

Keywords: duchenne muscular dystrophy, pediatric quality of life inventory disability paradox
single or repeat zoledronate versus alendronate following denosumab (european denosumab effects consolidation study)

Conditions: Osteoporosis, Postmenopausal

Summary: a 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab

125 postmenopausal women treated with dmab for 3 or more years who will reach osteopenia with denosumab will be randomized into three groups: i) zoledronate infusion (5mg) at 6 months after last dmab dose (single zol group) ii) zoledronate infusion (5mg) at 6 and 12 months after last dmab dose (double zol group) iii) alendronate 70mg orally weekly for 12 months (aln group) all women will receive no further treatment during the 2nd year of the study. participating centers: ects affiliated bone centers endpoints: primary: bmd changes at the lumbar spine at 12 months. secondary: i) bmd changes at the lumbar spine at 24 months; ii) bmd changes at the non-dominant femoral neck and total hip at 12 and 24 months; iii) changes at levels of bone turnover markers throughout the study; iv) incident fractures: vertebral (clinical and morphometric identified on vfa scans) and non-vertebral; v) clinical parameters: height change, vas for back pain, and use of analgesics

Eligibility criteria:
inclusion criteria: • postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia exclusion criteria: * a bone disease other than postmenopausal osteoporosis * use of medications other than bisphosphonates or serms affecting bone metabolism during the last 12 months before entering the study * creatinine clearance \<60 ml/min/1.73 m2 * liver failure * any type of cancer * uncontrolled endocrine diseases * serum 25-hydroxy vitamin d (25-ohd) concentrations lower than 20 ng/ml (50 nmol/l)
post-licensure safety study of imojev® in thailand

Conditions: Japanese Encephalitis

Summary: the aim of this study is to further characterize the safety profile of imojev®. primary objective: * to describe serious adverse events (saes, including adverse events of special interest \[aesis\]) up to 60 days after administration of one dose of imojev®. secondary objective: * to describe grade 3 (severe) systemic adverse events (aes) up to 30 minutes after administration of one dose of imojev®.

participants aged 1 year to less than 5 years will be randomized to receive one injection of imojev® either as a primary vaccination or as a booster. safety data will be collected for 60 days after imojev® vaccination. the duration of each subject's participation in the trial will be 60 days.

Eligibility criteria:
inclusion criteria: * children requiring vaccination against japanese encephalitis * children aged 9 months to less than 5 years on the day of inclusion * in good general health at the time of inclusion * informed consent form has been signed and dated by the parent(s)/legal guardian(s) * subject and parent(s)/legal guardian(s) are able to attend the scheduled visit and any additional visits that may need to be done in case of an sae (including aesi), and are able to comply with all trial procedures * the subject's parent(s)/legal guardian(s) have a telephone number at which they can be contacted throughout the study exclusion criteria: * participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the vaccination * receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination * planned participation in another clinical trial during the present trial period * children previously vaccinated with the live attenuated japanese encephalitis vaccine cd-jevax® (sa14-14-2 lav) * contraindications to vaccination according to the imojev® summary of product characteristics (smpc) * identified as a natural or adopted child of the investigator or employee with direct involvement in the proposed study * children who received imojev® as primary vaccination in this study.

Keywords: japanese encephalitis imojev® japanese encephalitis chimeric virus vaccine
suppression of oral hhv8 shedding with valganciclovir

Conditions: Human Herpesvirus 8

Summary: the purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of hhv-8 shedding in hhv-8 seropositive men. our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of hhv-8 in the mouth.

the purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of hhv-8 shedding in hhv-8 seropositive men. our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of hhv-8 in the mouth. such reduction will serve to confirm that the mouth is the site of active hhv-8 replication. if valganciclovir is found to be effective, the findings from this proposal would serve as the basis for a clinical trial with valganciclovir for prevention of kaposi's sarcoma (ks) in high-risk hhv-8 seropositive persons. after informed consent, all subjects will undergo medical history, physical examination and screening laboratory examination. eligible patients will return to clinic for randomization to receiver either valganciclovir 900 mg qd or placebo. participants will receive a diary for noting adverse events and concurrent medications. the clinician will instruct the participants on collection of mouth swabs and provide dacron swabs, vials with pcr media and pre-printed labels. subjects will be asked to obtain a swab of oral mucosa every morning. clinic visits every other week will serve to review interim medical history and diaries for adverse events, collect pcr swabs, dispense additional medication and draw safety labs. the study uses a double-blind, randomized placebo design. therefore, participants will not know whether they will be taking a placebo or active medication at any time during the study. due to the crossover study design, however, all participants will receive the same amount of placebo and study drug over the duration.

Eligibility criteria:
inclusion criteria: * 18 years or older * hhv-8 seropositive or previous evidence of hhv-8 shedding * a frequent shedder of hhv-8 * not receiving any drugs with known anti-hhv-8 activity for study duration * able to comply with the study protocol * agree to hiv testing exclusion criteria: * history of evidence of cmv disease * hypersensitivity to ganciclovir or valganciclovir * use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or cidofovir * neutropenia * renal insufficiency with serum creatinine greater than 1.5mg.ml or crcl less than 60 * ast or alt greater than 5 times upper limit of normal * concurrent administration of medications which are often associated with severe neutropenia or thrombocytopenia * concurrent administration of probenecid or didanosine
change in brain bioenergetics in bipolar disorder in response to photic stimulation

Conditions: Bipolar Disorder; Schizophrenia; Healthy Controls

Summary: this study aims to gather additional information to support the theory that bipolar disorder is due to cellular (mitochondrial) dysfunction. to test this theory adults with bipolar disorder who are not currently symptomatic will receive a one-time brain scan (magnetic resonance spectroscopy \[mrs\] scan) with light stimulation. to test whether any mrs findings are specific to bipolar disorder, healthy controls and adults with schizophrenia will also be included in this study.

this study will include males and females between the ages of 18 and 55 years. participants will include adults with stable bipolar disorder or schizophrenia as well as healthy controls. the study involves a one-time visit that includes a clinical evaluation, laboratory tests, and a magnetic resonance scan that will last approximately 90 minutes. the procedures can also be separated into two study visits, if necessary.

Eligibility criteria:
inclusion criteria: * male of female * 18-55 years * bipolar, currently euthymic or schizophrenia, stable, or healthy control with no history of psychiatric illness * on stable medication with no changes in the two weeks prior to enrollment exclusion criteria: * history of substance abuse or dependence within 3 months of enrollment * positive urine drug screen * significant medical or neurological illness * pregnancy * any contraindication to magnetic resonance scanning, including claustrophobia

Keywords: bipolar disorder schizophrenia healthy volunteer brain imaging photic stimulation
use of dental age determination methods in children with type diabetes

Conditions: Diabetes

Summary: the aim of this study was to determine the estimated dental age of children with type 1 diabetes by using cameriere, willems and demirjian methods.

the different metabolic activities of children with type 1 diabetes cause significant differences between them and healthy children. especially from a forensic point of view, special methods defined for these children are needed and dental age estimation is one of them. the aim of this study was to determine the estimated dental age of children with type 1 diabetes by using cameriere, willems and demirjian methods. methods: between 2017 and 2024, 58 patients with type 1 diabetes and healthy children were included in the study. dental ages were calculated on panoramic radiographic images by 2 different dentists using cameriere, willems and demirjian methods. dental ages and their differences with chronological ages were compared by group and gender. analyses were performed in ibm spss 25 program.

Eligibility criteria:
inclusion criteria: * 4-15 years old * no chronic disease in addition to the diagnosis of type 1 diabetes * children with controlled type 1 diabetes mellitus * no congenital tooth deficiency * pediatric patients with good quality panoramic radiographs were included. exclusion criteria: * blurred or distorted radiographs, * missing any of the left seven permanent mandibular teeth (genesis or extraction), * with dental abnormalities (dilaceration, supernumerary teeth) and developmental disorders (cleft lip and palate), * patients with incomplete medical or dental history were excluded.
treatment of hypoglycemia in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: according to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose \< 4.0 mmol/l), 15-20g of rapidly absorbed carbohydrates should be ingested. patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. these recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy secondary to the dcct trial and with insulin formulations with largely different pharmacokinetic profiles from current insulin analogs. recent studies suggest that with current insulin analogs and intensive therapeutic approach, 15g of carbohydrates may be insufficient to rapidly correct an important proportion of hypoglycemic episodes. it is thus important to determine if the recommended hypoglycemia treatment remains the recommendation.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years of old. 2. clinical diagnosis of type 1 diabetes for at least one year. 3. treatment with multiple daily insulin injections or insulin pump therapy and using insulin analogs (rapid, ultra-rapid and basal). 4. hba1c ≤ 10%. exclusion criteria: 1. clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 2. recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. known significant cardiac rhythm abnormality based on investigator judgment. 4. abnormal blood panel and/or anemia (hb \< 100g/l). 5. ongoing pregnancy or breastfeeding. 6. severe hypoglycemic episode within 1 month of screening. 7. known uncorrected hypokalemia (potassium \< 3.5 mmol/l; available within the past 3 months).

Keywords: hypoglycemia, carbohydrates
analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy

Conditions: Breast Cancer

Summary: this is a retrospective propensity score-matched analysis of a large institutional cohort of patients in order to compare long-term outcomes and clinicopathologic characteristics between patients treated with breast conserving surgery or mastectomy for breast cancer.

the aim of the study is to compare long-term outcomes and clinicopathologic characteristics between patients treated with breast conserving surgery + whole breast irradiation or mastectomy for breast cancer. recent observations regarding long-term outcomes among patients with early-stage breast cancer who underwent breast-conserving surgery plus whole-breast irradiation or mastectomy are from a small number of registry-based studies. therefore, these findings may overestimate differences in survival between the two groups, compared with randomized controlled trials conducted in the 1980s. this study performed a propensity score-matched analysis in a cohort of 9710 patients aged \<70 years who underwent breast conserving surgery + whole breast irradiation or mastectomy without external radiotherapy for a first primary breast cancer (pt1-2, n0-3a) at the european institute of oncology between 2000 and 2008. patients were matched by propensity score.

Eligibility criteria:
inclusion criteria: * first primary breast cancer * pt1-2 * pn0-3a * surgery performed at european institute of oncology between 2000 and 2008 exclusion criteria: * pt\>=3 * neoadjuvant treatment * presence of metastatic breast disease at the time of admission or within 3 months